# Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

> **NCT03240016** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT03240016
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-08
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03240016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03240016, "Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03240016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*